First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A. Chiappori, John A. Thompson, Toshihiko Doi, Siwen Hu-Lieskovan, Ferry A.L.M. Eskens, Willeke Ros, Adi Diab, Jean Philippe Spano, Naiyer A. Rizvi, Jeffrey S. Wasser, Eric Angevin, Patrick A. Ott, Alison Forgie, Wenjing Yang, Cen Guo, Jeffrey Chou, Anthony B. El-Khoueiry
Dive into the research topics of 'First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors'. Together they form a unique fingerprint.